Lung cancer remains a formidable challenge in the medical world, accounting for a quarter of all cancer deaths. The Canadian Cancer Society highlights a stark contrast in survival rates: 62% for Stage 1 diagnoses versus a mere 3% for Stage 4.
This disparity highlights the critical need for early detection tools. Dr. Stephen Lam, Professor of Medicine at the University of British Columbia, explained in a CBC interview, “All of these cancers were found in people who do not have symptoms suspicious of lung cancer such as hemoptysis (coughing up of blood), chest pain, weight loss or a change in breathing,”, illustrating the silent nature of early-stage lung cancer.
Marla Kott’s story is a poignant example of the disease’s impact. Diagnosed with Stage 4 lung cancer on her 60th birthday, Kott reflects, “It was not a great day.” Her journey mirrors the experiences of many who are diagnosed late due to the absence of early symptoms. Kott’s resilience, still going strong nine years later, underscores the need for a test that can catch the disease in its stages.
The proposed solution lies in a simple breath test.
“When we exhale, we exhale over 1,000 volatile organic compounds,” shares Dr. Renelle Myers, Clinical Associate professor of Medicine at University of British Columbia, hinting at the complexity and potential of our breath. Leveraging artificial intelligence (AI), the test seeks to identify specific chemical signatures in the breath that signal early lung cancer.
